Home
Osteoporosis Therapies: Strong Bones for Life
7 June - 8 June 2000
Osteoporosis Therapies: Strong Bones for Life
In the next fifteen years, the number of women who have, or are at risk of developing, osteoporosis will increase to over 35 million. The pharmacoeconomic implications of this are enormous and there is huge potential in the pharmaceutical market for osteoporosis, whether in the form of therapies, diagnostic techniques, disease management or prevention.

This conference offers you the opportunity to network with key industry experts, discover the potential of the osteoporosis market and learn about crucial advances in the treatment, diagnosis and understanding of this devastating disease. It will be informative, stimulating and focused. If you missed your opportunity last year, ensure you register this year, without delay.

Conference agenda

clock

8:30

Registration and coffee

clock

9:00

Therapeutic opportunities in osteoporosis

  • Post-menopausal osteoporosis
  • Glucocorticoid-induced osteoporosis
  • Male osteoporosis
  • Accelerated bone loss
  • clock

    9:30

    Exploiting opportunities in bone biology: pathophysiologic mechanisms as therapeutic targets

    clock

    10:00

    Evolution of registration requirements: Europe; United States

    clock

    10:15

    Developing an anti-osteoporotic drug I

  • Compound selection
  • Pre-clinical testing: impact on the clinical development pathway
  • Dose finding: the critical role of phase II
  • Role of biochemical markers of bone remodelling in compound selection and dose finding
  • clock

    10:45

    Morning coffee

    clock

    11:00

    Developing an anti-osteoporotic drug II

  • Bone densitometry and morphometry: role of the central laboratory
  • Fracture assessment
  • Cardiovascular and endometrial safety
  • clock

    11:30

    Organising the development process

  • Trial planning
  • Data collection and analysis: streamlining and co-ordination
  • clock

    12:00

    Case examples and discussion

    clock

    12:30

    Close of workshop

    clock

    13:30

    Registration and Coffee

    clock

    14:00

    Recruitment in osteoporosis trials: the right way and the wrong way

  • Availability of patients in the general population
  • Screening strategies using DXA
  • Recruitment methods
  • Optimising the speed of recruitment
  • The importance of combining quality with speed
  • Patient retention strategies
  • clock

    14:45

    Ethical considerations in performing clinical trials in osteoporosis

  • Recruitment strategies
  • Challenges for patient and investigator in conducting long term studies
  • Ethics: the role of the placebo
  • Ethnic considerations
  • Discussion
  • clock

    15:30

    Coffee

    clock

    16:00

    Evaluation of instruments in osteoporosis clinical trials

  • Improving manageability and cost in complex, expensive long-term osteoporosis trials
  • Diagnosing vertebral fractures in osteoporosis
  • Using imaging in osteoporosis clinical trials
  • Establishing product efficacy through imaging
  • Selecting and using an Imaging Core Laboratory
  • Discussion
  • clock

    16:45

    The future of clinical trials in osteoporosis - round table discussion

    clock

    17:30

    Close of workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dr Richard Keen

    Dr Richard Keen, , Senior Lecturer in Metabolic Bone Disease, Honorary Consultant Rheumatologist, University College London

    clock

    9:10

    IMPROVING RESEARCH AND UNDERSTANDING THROUGH INTEGRATION

    Prof John Wass

    Prof John Wass, Professor of Endocrinology, Nuffield Orthopaedic Centre

  • Providing a new base for medical research and therapeutic care
  • Integrating basic and clinical research, clinical care and scientific and patient education in hormone-related and metabolic diseases including osteoporosis
  • Improving the understanding and treatment of diseases
  • Facilitating the research efforts to find cures
  • Benefits for the patient
  • Benefits for the pharmaceutical industry
  • clock

    9:40

    IDENTIFYING SUSCEPTIBILITY GENES AND DRUG TARGETS IN OSTEOPOROSIS

    Dr Michael Dennis

    Dr Michael Dennis, President, Chief Executive Officer, SignalGene

  • Objectives of SignalGene’s research programme
  • Genetic susceptibility to osteoporosis
  • Nuclear receptor alleles as susceptibility genes
  • Genetic markers for response of osteoporosis patients to drug therapy
  • Strategies to accelerate validation of genetic targets in osteoporosis
  • clock

    10:20

    UNDERSTANDING THE GENETIC BASIS OF OSTEOPOROSIS

    Dr Simon Bennett

    Dr Simon Bennett, Programme Manager, Oxagen

  • Investigating the genetic basis of osteoporosis
  • Developing techniques for high-throughput genomics
  • Supporting clinical trial candidate selection and prescribing practices for existing therapeutics
  • Linking patient genotype, disease frequency, therapeutic profile and outcome
  • Advantages to health management organisations
  • Identifying opportunities for cost-effective treatment of osteoporosis
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    GENETICS OF BONE FORMATION AND DESTRUCTION

    Dr Simon van Dijk

    Dr Simon van Dijk, Head of Osteoporosis Research Programme, Interleukin Genetics

  • The role of IL-1 proteins in osteoporosis
  • Genetic variations in the IL-1 gene cluster
  • IL-1 proteins and their role in the inflammatory response
  • How the gene cluster influences the development and progression rate of osteoporosis
  • Developing genetic susceptibility tests for osteoporosis
  • Explaining patients’ variation in the severity of disease expression
  • clock

    12:00

    IN SEARCH OF GENES

    Dr Patrick Kleyn

    Dr Patrick Kleyn, Chief Scientific Officer, Gemini Research

  • Providing a research and development discovery programme
  • Building a genetic information database
  • Determining the genetic basis of osteoporosis
  • Understanding the multifactorial and polygenic basis of osteoporosis
  • Establishing relationships between genetic constitution and susceptibility to osteoporosis
  • Identification of diagnostic probes
  • clock

    12:40

    Lunch

    clock

    14:00

    OSTEOPOROSIS TESTING: ASSESSMENT OF FRACTURE RISK

    Dr Eric von Stetten

    Dr Eric von Stetten, Scientific Director, Hologic

  • Bone loss and vertebral fractures: the two strongest risk factors for subsequent fracture
  • Detecting bone loss
  • Detecting vertebral fractures
  • Integrated evaluation of bone density and vertebral fractures
  • Implications for clinical patient evaluation
  • Opportunities for improved targeting of therapy and acceptance and compliance with therapy
  • clock

    14:40

    DIAGNOSING AND MONITORING OSTEOPOROSIS

    Dr Louai Al-Dayeh

    Dr Louai Al-Dayeh, Scientific Director, CompuMed

  • The importance of bone density measurements in osteoporosis
  • Methods for analysing bone density
  • Developing the Automated Osteogram® for osteoporosis monitoring
  • How the Automated Osteogram® works
  • Developments in bone density research
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    BONE DENSITOMETRY SYSTEMS

    Reynald Bonmati

    Reynald Bonmati, Chairman, Chief Executive Officer, Norland Medical Systems

  • Developing bone measurement systems
  • Diagnosing and monitoring osteoporosis
  • Use of bone mass and bone density analysis in diagnosing osteoporosis
  • Involving x-ray, ultrasound and peripheral scanning
  • Further advances in musculoskeletal diagnostics and therapies
  • clock

    16:20

    MEASURING BONE DENSITY IN OSTEOPOROSIS

    Dr Jef Van Dam

    Dr Jef Van Dam, Area Sales Manager, Lunar

  • Requirements for accuracy and precision
  • Reference values: T-scores and Z-scores
  • Fracture risk and bone density
  • Ultrasonometry predicts hip fractures
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day One

    clock

    17:10

    Drinks reception for delegates and speakers

    clock

    8:30

    Re-registration and Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dr Juliet Compston

    Dr Juliet Compston, Reader in Metabolic Bone Disease, Honorary Consultant Physician, University of Cambridge

    clock

    9:10

    IMPLEMENTATION OF REGULATIONS AND GUIDELINES ON OSTEOPOROSIS

    Dr Ilona GroBe-Michaelis

    Dr Ilona GroBe-Michaelis, Specialist in Pharmacology and Toxicology, Schering

  • Comparison of current guidelines (Sept 1997) and the new draft guidelines (Sept 1999)
  • Implementation of the guidelines within Schering
  • Practical experience within the indication prevention of osteoporosis
  • Osteopenic patient population
  • Stratification according to post-menopausal age
  • Influence of central quality control on BMD data
  • clock

    9:40

    NEW INDICATIONS FOR EXISTING SERM THERAPIES

    Dr Donato Agnusdei

    Dr Donato Agnusdei, European Medical Co-ordinator, Eli Lilly

  • Clinical profile of Evista
  • Providing a new therapy option for post-menopausal women
  • From prevention to treatment of post-menopausal osteoporosis
  • Multiple Outcomes of Raloxifene Evaluation (The MORE Trial)
  • Preventing fractures and reducing the burden of illness
  • Anticipating the future of SERM therapies
  • clock

    10:20

    TOWARDS NOVEL ANTI-RESORPTIVE AND ANABOLIC THERAPIES

    Dr John K Westwick

    Dr John K Westwick, Group Leader, Target Biology, Signal Pharmaceuticals

  • Discovering novel SERMs with favourable profiles and ER specificity
  • Demonstrating in vivo efficacy in animal models of osteoporosis
  • Mining BMP signal transduction pathways for discovery of novel anabolic targets
  • Discovering endogenous modulators of BMP signalling
  • High through-put screening on novel targets for detecting anabolic agents
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    ANABOLIC THERAPIES FOR OSTEOPOROSIS

    Dr Edward Nemeth

    Dr Edward Nemeth, Vice President, Chief Scientific Officer, NPS Pharmaceuticals

  • Exogenous PTH: clinical results with systemically-administered hormones (ALX1-11)
  • Dose-related increases in vertebral BMD and bone markers
  • Well-tolerated with few episodes of only transient hypercalcemia
  • Endogenous PTH: pre-clinical results with orally administered calcilytic compounds
  • Calcilytics block parathyroid calcium receptor and stimulate PTH secretion
  • Calcilytics stimulate new bone formation in ovariectomised rats
  • clock

    12:00

    OSTEOPOROSIS AND THE OESTROGEN RECEPTOR

    Dr Andres Negro-Vilar

    Dr Andres Negro-Vilar, Chief Scientific Officer, Senior Vice President of Research, Ligand Pharmaceuticals

  • Researching and developing small molecule compounds for treatment of osteoporosis
  • Oestrogen receptor technology
  • Beneficial effects of small-molecule compounds in osteoporosis
  • Treating and preventing disease mediated through the oestrogen receptor
  • Advantages of research and development collaborations
  • Strengthening its research position to work towards unmet medical needs
  • clock

    12:40

    Lunch

    clock

    13:40

    A NOVEL APPROACH TO OSTEOPOROSIS THERAPIES

    Dr Andreas Sommer

    Dr Andreas Sommer, Consultant, Insmed Pharmaceuticals

  • SomatoKine, a DNA derived protein complex
  • Mechanism of action of SomatoKine
  • SomatoKine’s potential involvement in regenerating bones and muscles
  • Finishing phase II clinical trials to study the effects of SomatoKine on muscle and bone loss after hip surgery
  • Benefit for the patient
  • Securing their position within the marketplace
  • clock

    14:20

    BONE DENSITY AND CHOLESTEROL

    Prof Alan Husband

    Prof Alan Husband, Research Director, Novogen

  • The relationship between menopause, cholesterol and osteoporosis
  • Isoflavone dietary supplement (P-081) - the active ingredient in Rimosti™
  • Falling HDL levels leading to increasing problems for post-menopausal women
  • Restoring pre-menopausal HDL levels
  • Delivering the desired clinical effect in the right dosage
  • Providing benefits for the patients
  • clock

    15:00

    BISPHOSPHONATES: PHARMACEUTICAL REDUCTION OF FRACTURE RISKS

    Dr Simon Pack

    Dr Simon Pack, Section Head, Biometrics and Statistical Sciences, Procter & Gamble

  • Therapeutic need
  • Introduction to bisphosphonates
  • The risedronate programme
  • Risedronate’s vertebral and non-vertebral efficacy
  • Safety and tolerability of risedroante
  • Current and future developments in osteoporosis
  • clock

    15:40

    Afternoon Tea

    clock

    16:00

    OSTEOPOROSIS: PRECLINICAL DRUG DEVELOPMENT

    Dr Steven D Bain

    Dr Steven D Bain, Executive Vice President, Chief Scientific Officer, Skeletech

  • Drug discovery and the pre-clinical bottleneck
  • Optimisation and management of preclinical development programmes
  • Model systems for evaluating the next generation of osteoporosis drugs
  • Role of information management in osteoporosis drug development
  • Leveraging osteoporosis drug therapies into other therapeutic applications
  • clock

    16:30

    CONTRIBUTIONS TO OSTEOPOROSIS RESEARCH

    Dr Solomon Epstein

    Dr Solomon Epstein, Chief Medical Director, Roche Laboratories

  • Shifting the medical paradigm to benefit the osteoporosis patient
  • The role of IV therapy in the management of osteoporosis
  • Benefits of IV therapy compared to current therapies
  • Providing a comprehensive healthcare management programme for the osteoporosis patient
  • clock

    17:00

    Chairman's Closing Remarks and Close of Conference

    Workshops

    Product Development: Providing An Integrated Approach

    Product Development: Providing An Integrated Approach

    The Hatton, at etc. venues
    6 June 2000
    London, United Kingdom

    Performing Successful Clinical Trials in Osteoporosis

    Performing Successful Clinical Trials in Osteoporosis

    The Hatton, at etc. venues
    6 June 2000
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.